Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Sep;37(9):1771–1776. doi: 10.1128/aac.37.9.1771

The time of administration of 3'-azido-3'-deoxythymidine (AZT) determines its host toxicity with possible relevance to AZT chemotherapy.

R Zhang 1, Z Lu 1, C R Diasio 1, T Liu 1, S J Soong 1
PMCID: PMC188068  PMID: 8239582

Abstract

3'-Azido-3'-deoxythymidine (AZT) is the drug most widely used in the treatment of AIDS. Its major drug-related toxicity is bone marrow suppression, which limits the dose of AZT that can be used. It is essential that AZT be phosphorylated for antiviral effect. We have recently demonstrated that thymidine kinase (TK), the initial enzyme in AZT anabolism, follows a circadian pattern in rat bone marrow. The present study was undertaken to determine whether AZT toxicity is related to the time of its administration and whether the variation in toxicity is correlated with the circadian variation in TK activity. Male Sprague-Dawley rats were housed under standardized conditions of light and dark (lights on 0600 to 1800 and lights off 1800 to 0600) for 4 weeks. The animals were randomly divided into seven groups; six groups were administered AZT by intraperitoneal injection at the same dose of 750 mg/kg of body weight at various times (0400, 0800, 1200, 1600, 2000, and 2400), and one group was used as a control. AZT-related toxic effects, including bone marrow toxicity, differed significantly among the treatment groups, depending on the time of AZT administration (by analysis of variance and Cosinor analysis, P < 0.001). The least toxicity was observed in rats receiving AZT at 1600 (10 h after light onset [10 HALO], in late sleep span) and the greatest toxicity was observed in those injected at 0400 (22 HALO, in late activity span). To verify these results, we administered AZT by intraperitoneal injection at an approximately 50% lethal dose (1,500 mg/kg) to two groups of rats, one at 1200 (6 HALO, in the middle of the sleep span) and the other at 2400 (18 HALO, in the middle of the activity span). AZT lethality was significantly higher in rats receiving AZT at 2400 (18 HALO, in the middle of the activity span). Further statistical analysis demonstrated that the variation in AZT toxicity was correlated with the circadian variation in TK activity in bone marrow of the same species (peak activity at 0400 [22 HALO, in late activity span] and trough activity at 1600 [10 HALO, in late sleep span]), suggesting that the circadian variation in TK activity may be the biochemical basis for the observed circadian variation in AZT toxicity. These results may be useful in the design of improved AZT chemotherapeutic regimens.

Full text

PDF
1771

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bridges E. G., Faraj A., Sommadossi J. P. Inhibition of mammalian DNA polymerase-associated 3' to 5' exonuclease activity by 5'-monophosphates of 3'-azido-3'-deoxythymidine and 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1993 Apr 22;45(8):1571–1576. doi: 10.1016/0006-2952(93)90296-9. [DOI] [PubMed] [Google Scholar]
  2. Daher G. C., Zhang R. W., Soong S. J., Diasio R. B. Circadian variation of fluoropyrimidine catabolic enzymes in rat liver: possible relevance to 5-fluorodeoxyuridine chemotherapy. Drug Metab Dispos. 1991 Jan-Feb;19(1):285–287. [PubMed] [Google Scholar]
  3. Finney D. J. The median lethal dose and its estimation. Arch Toxicol. 1985 Feb;56(4):215–218. doi: 10.1007/BF00295156. [DOI] [PubMed] [Google Scholar]
  4. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  5. Furman P. A., Barry D. W. Spectrum of antiviral activity and mechanism of action of zidovudine. An overview. Am J Med. 1988 Aug 29;85(2A):176–181. [PubMed] [Google Scholar]
  6. Furman P. A., Fyfe J. A., St Clair M. H., Weinhold K., Rideout J. L., Freeman G. A., Lehrman S. N., Bolognesi D. P., Broder S., Mitsuya H. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333–8337. doi: 10.1073/pnas.83.21.8333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hrushesky W. J., Von Roemeling R., Fraley E. E., Rabatin J. T. Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma. Semin Surg Oncol. 1988;4(2):110–115. [PubMed] [Google Scholar]
  8. Hrushesky W. J., von Roemeling R., Lanning R. M., Rabatin J. T. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol. 1990 Sep;8(9):1504–1513. doi: 10.1200/JCO.1990.8.9.1504. [DOI] [PubMed] [Google Scholar]
  9. Morse G. D., Portmore A. C., Marder V., Plank C., Olson J., Taylor C., Bonnez W., Reichman R. C. Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients. Antimicrob Agents Chemother. 1992 Oct;36(10):2245–2252. doi: 10.1128/aac.36.10.2245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Sletvold O., Smaaland R., Laerum O. D. Cytometry and time-dependent variations in peripheral blood and bone marrow cells: a literature review and relevance to the chronotherapy of cancer. Chronobiol Int. 1991;8(4):235–250. doi: 10.3109/07420529109063929. [DOI] [PubMed] [Google Scholar]
  11. Smaaland R., Laerum O. D., Lote K., Sletvold O., Sothern R. B., Bjerknes R. DNA synthesis in human bone marrow is circadian stage dependent. Blood. 1991 Jun 15;77(12):2603–2611. [PubMed] [Google Scholar]
  12. Smaaland R., Svardal A. M., Lote K., Ueland M., Laerum O. D. Glutathione content in human bone marrow and circadian stage relation to DNA synthesis. J Natl Cancer Inst. 1991 Aug 7;83(15):1092–1098. doi: 10.1093/jnci/83.15.1092. [DOI] [PubMed] [Google Scholar]
  13. Sothern R. B., Rhame F., Suarez C., Fletcher C., Sackett-Lundeen L., Haus E., Hrushesky W. J. Oral temperature rhythmometry and substantial within-day variation in zidovudine levels following steady-state dosing in human immunodeficiency virus (HIV) infection. Prog Clin Biol Res. 1990;341A:67–76. [PubMed] [Google Scholar]
  14. Swoyer J., Rhame F., Hrushesky W., Sackett-Lundeen L., Sothern R., Gale H., Haus E. Circadian rhythm alteration in HIV infected subjects. Prog Clin Biol Res. 1990;341A:437–449. [PubMed] [Google Scholar]
  15. Taylor A. T., Stafford M. A., Jones O. W. Properties of thymidine kinase partially purified from human fetal and adult tissue. J Biol Chem. 1972 Mar 25;247(6):1930–1935. [PubMed] [Google Scholar]
  16. Thompson M. B., Dunnick J. K., Sutphin M. E., Giles H. D., Irwin R. D., Prejean J. D. Hematologic toxicity of AZT and ddC administered as single agents and in combination to rats and mice. Fundam Appl Toxicol. 1991 Jul;17(1):159–176. doi: 10.1016/0272-0590(91)90248-3. [DOI] [PubMed] [Google Scholar]
  17. Yarchoan R., Mitsuya H., Myers C. E., Broder S. Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med. 1989 Sep 14;321(11):726–738. doi: 10.1056/NEJM198909143211106. [DOI] [PubMed] [Google Scholar]
  18. Zhang R., Lu Z., Liu T., Soong S. J., Diasio R. B. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. Cancer Res. 1993 Jun 15;53(12):2816–2822. [PubMed] [Google Scholar]
  19. Zhu Z., Hitchcock M. J., Sommadossi J. P. Metabolism and DNA interaction of 2',3'-didehydro-2',3'-dideoxythymidine in human bone marrow cells. Mol Pharmacol. 1991 Nov;40(5):838–845. [PubMed] [Google Scholar]
  20. von Roemeling R., Hrushesky W. J. Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. J Clin Oncol. 1989 Nov;7(11):1710–1719. doi: 10.1200/JCO.1989.7.11.1710. [DOI] [PubMed] [Google Scholar]
  21. von Roemeling R., Hrushesky W. J. Determination of the therapeutic index of floxuridine by its circadian infusion pattern. J Natl Cancer Inst. 1990 Mar 7;82(5):386–393. doi: 10.1093/jnci/82.5.386. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES